Compare · IRIX vs TMDX
IRIX vs TMDX
Side-by-side comparison of IRIDEX Corporation (IRIX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRIX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.65B, about 183.2x IRIX ($14.5M).
- IRIX has been more active in the news (7 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (20 ratings vs 0 for IRIX).
- Company
- IRIDEX Corporation
- TransMedics Group Inc.
- Price
- $0.86+3.93%
- $70.82-7.52%
- Market cap
- $14.5M
- $2.65B
- 1M return
- -
- -18.36%
- 1Y return
- -
- -39.77%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2019
- News (4w)
- 7
- 2
- Recent ratings
- 0
- 20
IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest IRIX
- SEC Form 4 filed by IRIDEX Corporation
- Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
- SEC Form 4 filed by IRIDEX Corporation
- SEC Form 4 filed by IRIDEX Corporation
- SEC Form 4 filed by IRIDEX Corporation
- SEC Form 4 filed by IRIDEX Corporation
- Iridex Completes Relocation of Manufacturing Facility to San Jose, California
- Chief Financial Officer Dizon Romeo R bought $4,977 worth of shares (7,900 units at $0.63), increasing direct ownership by 4% to 185,306 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $1,530 worth of shares (2,354 units at $0.65), increasing direct ownership by 1% to 177,406 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $3,468 worth of shares (5,100 units at $0.68), increasing direct ownership by 3% to 175,052 units (SEC Form 4)
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results